INO-4201 / Inovio - LARVOL DELTA

Safety and immunogenicity of the DNA vaccine candidate INO-4201 followed by electroporation as booster vaccination in healthy, rVSV-ZEBOV-primed volunteers: an investigator-initiated phase Ib, placebo-controlled, randomised clinical trial (Boost-EBOV) (ECCMID 2023) - No abstract available

Clinical • Late-breaking abstract

Boost-EBOV: INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: University of Geneva, Switzerland | Not yet recruiting ➔ Completed | Trial primary completion date: Apr 2022 ➔ Jan 2022

Trial completion • Trial primary completion date • Infectious Disease

Boost-EBOV: INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (clinicaltrials.gov) - P1; N=50; Not yet recruiting; Sponsor: University of Geneva, Switzerland

Clinical • New P1 trial • Infectious Disease

Intradermal SynCon® Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. (PubMed, J Infect Dis) - P1; "Intradermal delivery of INO-4201 was well-tolerated and resulted in 100% seroreactivity after two doses and elicited interferon-γ T cell responses in over 70% of subjects, providing a new approach for EBOV prevention in diverse populations."

Clinical • Journal